

Frederic Rolland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/936547/publications.pdf>

Version: 2024-02-01

42
papers

12,994
citations

186265

28
h-index

265206

42
g-index

42
all docs

42
docs citations

42
times ranked

12513
citing authors

#	ARTICLE	IF	CITATIONS
1	Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study. <i>Cancers</i> , 2022, 14, 1678.	3.7	7
2	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. <i>Cancer Discovery</i> , 2022, 12, 1435-1448.	9.4	28
3	Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC Tj ETQq1 1 0,784314 rgBT /Ovett). <i>Journal of Clinical Oncology</i> , 2014, 32, 463-475.	10.7	95
4	An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. <i>Nature Medicine</i> , 2021, 27, 793-801.	30.7	56
5	Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 554-562.	1.9	6
6	Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Étude des Tumeurs Uro-Génitales). <i>European Journal of Cancer</i> , 2021, 158, 1-11.	2.8	4
7	Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients. <i>International Journal of Cancer</i> , 2020, 146, 1643-1651.	5.1	5
8	Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study. <i>European Journal of Cancer</i> , 2019, 123, 36-47.	2.8	21
9	Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy. <i>JAMA Oncology</i> , 2019, 5, 623.	7.1	25
10	Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. <i>European Urology</i> , 2018, 73, 696-703.	1.9	45
11	Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3077-3083.	1.6	107
12	Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. <i>European Urology</i> , 2016, 70, 256-262.	1.9	355
13	Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 85-92.	0.8	28
14	Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project. <i>Annals of Oncology</i> , 2015, 26, 2392-2398.	1.2	25
15	Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 787-794.	10.7	206
16	Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. <i>European Urology</i> , 2015, 68, 196-204.	1.9	102
17	Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). <i>European Journal of Cancer</i> , 2014, 50, 953-962.	2.8	63
18	Phase I trial of oral etoposide in combination with radiotherapy in head and neck squamous cell carcinoma - GORTEC 2004-02. <i>Radiation Oncology</i> , 2013, 8, 40.	2.7	6

#	ARTICLE	IF	CITATIONS
19	Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 149-158.	10.7	586
20	Are Tyrosine Kinase Inhibitors Still Active in Patients With Metastatic Renal Cell Carcinoma Previously Treated With a Tyrosine Kinase Inhibitor and Everolimus? Experience of 36 Patients Treated in France in the RECORD-1 Trial. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 128-133.	1.9	14
21	Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: Review of the literature and proposal for management changes. <i>Oral Oncology</i> , 2013, 49, 482-491.	1.5	41
22	Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPIN Randomized Phase II Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 853-859.	1.6	358
23	Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 482-487.	1.6	156
24	A phase III trial of docetaxel+estramustine in high-risk localised prostate cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trial. <i>European Journal of Cancer</i> , 2012, 48, 209-217.	2.8	47
25	Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2011, 12, 673-680.	10.7	220
26	Gemcitabine or Gemcitabine Plus Oxaliplatin in the First-Line Treatment of Patients With Advanced Transitional Cell Carcinoma of the Urothelium Unfit for Cisplatin-Based Chemotherapy: A Randomized Phase 2 Study of the French Genitourinary Tumor Group (GETUG V01). <i>European Urology</i> , 2011, 60, 1251-1257.	1.9	29
27	Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a α T lymphocyte agonist in patients with solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1521-1530.	4.2	84
28	Evaluation of the safety, pharmacokinetics and treatment effects of an α integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010, 6, 42-48.	1.1	43
29	Amplification of epidermal growth factor receptor gene in renal cell carcinoma. <i>European Journal of Cancer</i> , 2010, 46, 859-862.	2.8	11
30	Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 3312-3318.	1.6	1,007
31	Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1280-1289.	1.6	463
32	Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma. <i>Investigational New Drugs</i> , 2009, 27, 482-489.	2.6	37
33	Do Patients With Advanced Urothelial Carcinoma Benefit From Weekly Paclitaxel Chemotherapy? A GETUG Phase II Study. <i>Clinical Genitourinary Cancer</i> , 2009, 7, E28-E33.	1.9	43
34	Phase-I study of Innacell α , an autologous cell-therapy product highly enriched in α T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1599-1609.	4.2	211
35	Lapatinib Versus Hormone Therapy in Patients With Advanced Renal Cell Carcinoma: A Randomized Phase III Clinical Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 2285-2291.	1.6	90
36	Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 2171-2177.	1.6	898

#	ARTICLE	IF	CITATIONS
37	Prospective Multicenter Phase II Study of Gemcitabine Plus Platinum Salt for Metastatic Collecting Duct Carcinoma: Results of a GETUG (Groupe d'Études des Tumeurs Uro-Génitales) Study. <i>Journal of Urology</i> , 2007, 177, 1698-1702.	0.4	160
38	Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2007, 356, 125-134.	27.0	4,569
39	Preliminary results of the Prostacox phase II trial in hormonal refractory prostate cancer. <i>BJU International</i> , 2007, 100, 770-774.	2.5	15
40	Bilateral Breast Metastases From Ewing Sarcoma of the Femur. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 102-103.	1.3	7
41	Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer. <i>New England Journal of Medicine</i> , 2004, 350, 1945-1952.	27.0	2,704
42	A Phase II study of irinotecan in patients with advanced renal cell carcinoma. <i>Cancer</i> , 2003, 98, 61-65.	4.1	17